You are here

Bristol-Myers Squibb (BMS)

Member Since 2004

Giovanni Caforio, MD

Chairman of the Board and Chief Executive Officer

Mr. Dr. Giovanni Caforio, M.D., serves as the Chief Executive Officer of Bristol-Myers Squibb Australia Pty Ltd. Dr. Caforio serves as Chief Operating Officer at Medarex, Inc. He has responsibility for leading a fully integrated worldwide commercial organization and Medarex-wide functions of Enterprise Services and Global Manufacturing & Supply. He has been the Chief Executive Officer of Bristol-Myers Squibb Company since May 5, 2015. He served as Chief Operating Officer Myers Squibb Company since June 9, 2014 and also served as its Chief Commercial Officer and Executive Vice President since November 13, 2013. Dr. Caforio leads the Bristol-Myers Squibb Company's pharmaceutical business in the U.S. He served as Chief Commercial Officer at Medarex, Inc. Dr. Caforio served as the President of U.S. Pharmaceuticals at Bristol-Myers Squibb Company since October 2011. He served as Senior Vice President of U.S. Oncology, Worldwide Pharmaceuticals at Bristol-Myers Squibb Company from 2007 to 2009. He served as Senior Vice President of Global Commercialization, Oncology and Immunology at Bristol-Myers Squibb from January 2011 to October 2011 and its Senior Vice President of Oncology, Global Commercialization from 2009 to 2010, where he helped re-establish Bristol-Myers Squibb as a leader in Oncology, including the launch of YERVOY™, the Bristol-Myers Squibb's innovative immuno-oncology medicine for metastatic melanoma. As a leader, his focus is on developing talented leaders with the diverse experiences and competencies needed for the continued success of the Bristol-Myers Squibb Company. He joined Bristol-Myers Squibb in 2000 as Vice President and General Manager of Italy, in the Worldwide Medicines Group. In 2001, he assumed added responsibility for Greece and Israel, and then all of South East Europe in 2003. Since 2004, he served as Senior Vice President of European Marketing and Brand Commercialization of Bristol-Myers Squibb. Since 2007, he served as Senior Vice President of U.S. Oncology of Bristol-Myers Squibb. Prior to joining Bristol-Myers Squibb, he spent 12 years with Abbott Laboratories in a number of leadership positions. He has been a Director of Bristol-Myers Squibb Company since June 9, 2014. He served as a Director of Capital Health System, Inc. until June 17, 2016. Dr. Caforio holds an M.D. from the University of Rome.

CEO Cancer Gold Standard™

Gold Standard  Employer

Gold Standard Employer Since 2016 | Gold Standard China Employer Since 2018

Quote

Receiving the CEO Cancer Gold Standard Accreditation underscores Bristol-Myers Squibb’s commitment to transforming cancer care as well as our unwavering commitment to our patients and our people.

— Giovanni Caforio, MD

Gold Standard  Task Force Participation

Task Force Member(s): David Shepperly, MD, MHS, FACOEM, Head of Employee Health and Fitness

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Christopher Boerner PhD, President and Head US; Fouad Namouni MD, Oncology Development Head

Bristol-Myers Squibb (BMS)

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.
Around the world, our medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS and, rheumatoid arthritis.

At Bristol-Myers Squibb, our BioPharma strategy uniquely combines the reach and resources of a major pharma company with the entrepreneurial spirit and agility of a successful biotech company. With this strategy, we focus on our customers’ needs, giving maximum priority to accelerating pipeline development, delivering sales growth and continuing to manage costs.

The strategy is working. In recent years our total return for shareholders, including dividends, has been among the best in the industry. We outperformed most mega pharma companies, diversified companies and pure biotech companies. Reflecting our long-standing commitment to deliver shareholder value, our company has paid dividends to stockholders for more than 300 consecutive quarters.

We have delivered 12 new medicines to patients in the past 7 years.

Our R&D organization is considered among the most productive in the industry. And the business development strategy of innovative alliances, partnerships and acquisitions further enhances our internal capabilities. Our full array of transactions encompasses many of our key disease areas, along with new areas of focus such as genetically defined diseases and fibrotic diseases.

Pursuing our Mission also means we are working to provide patient access to health care. We are striving to reach that goal through public/private partnerships like SECURE THE FUTURE, our groundbreaking $150 million program to help confront HIV/AIDS in Africa while also developing new, innovative programs to help patients with cancer, hepatitis B and hepatitis C. In addition, through our patient assistance programs, we provide free medications to qualifying patients with financial hardship in the U.S.
Innovation is critical for successfully executing our BioPharma strategy. That innovation is enhanced by a diverse workforce and an inclusive culture. Bristol-Myers Squibb has been recognized year after year as one of the best companies for female executives and working mothers. We’ve also been recognized by the Human Rights Campaign Foundation’s Corporate Equality Index for achieving a perfect score for four consecutive years.

Preservation of our natural resources also represents one of our key commitments. At many of our facilities worldwide, our company is integrating comprehensive energy management, pollution controls and other practices to reduce environmental impacts. Bristol-Myers Squibb is recognized among the leading sustainability-driven companies.

Ultimately, our success as a BioPharma leader is measured by the difference we make in the lives of patients.